Virtus ETF Advisers’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Virtus ETF Advisers’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,601	Closed	-$342K	–	414
2020 Q4	$342K	Sell	2,601 -4,144	-61%	-$366K	0.14%	177
2020 Q3	$341K	Sell	6,745 -924	-12%	-$41.5K	0.18%	196
2020 Q2	$366K	Buy	7,669 +2,002	+35%	+$93.1K	0.17%	247
2020 Q1	$278K	Sell	5,667 -814	-13%	-$41.5K	0.11%	236
2019 Q4	$372K	Sell	6,481 -1,566	-19%	-$77.5K	0.06%	280
2019 Q3	$289K	Sell	8,047 -448	-5%	-$17.5K	0.06%	200
2019 Q2	$264K	Sell	8,495 -9,109	-52%	-$247K	0.06%	263
2019 Q1	$413K	Sell	17,604 -2,072	-11%	-$33.2K	0.88%	36
2018 Q4	$271K	Buy	+19,676	New	+$248K	0.05%	146

Virtus ETF Advisers's EIDX Position: Q1 2021 in Review

Virtus ETF Advisers sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 2,601 shares — an estimated $342K sold.

Virtus ETF Advisers first reported a position in EIDX in Q4 2018 and held it in 9 quarters. The position peaked at $413K in Q1 2019. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Virtus ETF Advisers reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Virtus ETF Advisers sold 2,601 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $342K.
Virtus ETF Advisers first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2018 and held it in 9 quarters.
Virtus ETF Advisers's Eidos Therapeutics, Inc. Common Stock position peaked at $413K in Q1 2019.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Virtus ETF Advisers's 13F filing for Q1 2021, filed 17 May 2021.